
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is demonstrating significant potential in the oncology sector with its pipeline candidate BDTX-1535, which has shown a 36% objective response rate (ORR) among evaluable patients with challenging EGFR mutations, improving to 42% when excluding those without on-target resistance mutations. The company's development focus on non-classical EGFR non-small cell lung cancer (NSCLC) positions it well, as this patient population is underserved by existing therapies, suggesting a substantial market opportunity. Additionally, with 74% of patients remaining on treatment as of the latest data cut, there is a positive indication for the drug's durability and further development, with data updates expected in 2025 to continue validating the favorable outlook.
Bears say
Black Diamond Therapeutics Inc faces significant risks associated with its drug candidate BDTX-1535, including potential negative efficacy data that could adversely impact its market viability. The company is also grappling with long-term dilution risks and has adjusted its expense assumptions and commercialization timeline, leading to a downward revision of its target price. Financial projections indicate a continued trend of net losses, with an anticipated net loss of $1.32 per share for the full year of 2025, reflecting ongoing operational challenges.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares